Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue: 2019-2022

Historic Non-Current Deffered Revenue for Revolution Medicines (RVMD) over the last 3 years, with Sep 2022 value amounting to $5.4 million.

  • Revolution Medicines' Non-Current Deffered Revenue fell 44.02% to $5.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.4 million, marking a year-over-year decrease of 44.02%. This contributed to the annual value of $6.6 million for FY2021, which is 22.50% down from last year.
  • Per Revolution Medicines' latest filing, its Non-Current Deffered Revenue stood at $5.4 million for Q3 2022, which was up 41.20% from $3.8 million recorded in Q2 2022.
  • Revolution Medicines' Non-Current Deffered Revenue's 5-year high stood at $14.7 million during Q4 2019, with a 5-year trough of $3.8 million in Q2 2022.
  • Over the past 3 years, Revolution Medicines' median Non-Current Deffered Revenue value was $8.1 million (recorded in 2021), while the average stood at $8.1 million.
  • Data for Revolution Medicines' Non-Current Deffered Revenue shows a maximum YoY plummeted of 49.65% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows Revolution Medicines' Non-Current Deffered Revenue stood at $14.7 million in 2019, then crashed by 42.41% to $8.5 million in 2020, then declined by 22.50% to $6.6 million in 2021, then slumped by 44.02% to $5.4 million in 2022.
  • Its last three reported values are $5.4 million in Q3 2022, $3.8 million for Q2 2022, and $5.7 million during Q1 2022.